2. Academic Validation
  3. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

  • Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149. doi: 10.1038/s41401-020-0485-4.
Yuan Huang 1,  Chan Yang 1,  Xin-Feng Xu 1,  Wei Xu 2,  Shu-Wen Liu 3 4
Affiliations

Affiliations

  • 1 Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
  • 2 Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China. [email protected].
  • 3 Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China. [email protected].
  • 4 State Key Laboratory of Organ Failure Research, Southern Medical University, Guangzhou, 510515, China. [email protected].
PMID: 32747721 DOI: 10.1038/s41401-020-0485-4
Abstract

Coronavirus disease 2019 is a newly emerging infectious disease currently spreading across the world. It is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The spike (S) protein of SARS-CoV-2, which plays a key role in the receptor recognition and cell membrane fusion process, is composed of two subunits, S1 and S2. The S1 subunit contains a receptor-binding domain that recognizes and binds to the host receptor angiotensin-converting Enzyme 2, while the S2 subunit mediates viral cell membrane fusion by forming a six-helical bundle via the two-heptad repeat domain. In this review, we highlight recent research advance in the structure, function and development of antivirus drugs targeting the S protein.

Keywords

SARS-CoV-2 virus; antibodies; antivirus drugs; fusion inhibitors; host proteases inhibitors; spike protein.

Figures